PBYI - Puma Biotechnology says European patent board upholds patent covering EGFR inhibitors

Puma Biotechnology ([[PBYI]] -5.7%) said the European Board of Appeals has rejected the opposition to EP Patent 1848414 initiated by a Boehringer Ingelheim entity.EP Patent 1848414, originally granted in April 2011 covers the use of irreversible EGFR inhibitors in treating gefitinib and/or erlotinib resistant cancer and cancer with a T790M EGFR mutation.At a final hearing, the Board of Appeals announced its decision, concluding that the opposition was inadmissible and reversing the European Opposition Division decision issued in 2014, thereby upholding the EP Patent 1848414 as originally granted.

For further details see:

Puma Biotechnology says European patent board upholds patent covering EGFR inhibitors